NASDAQ:HTBX - Heat Biologics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.20 +0.14 (+6.80 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$2.20
Today's Range$2.02 - $2.32
52-Week Range$1.09 - $7.90
Volume2.00 million shs
Average Volume1.26 million shs
Market Capitalization$36.52 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97

About Heat Biologics (NASDAQ:HTBX)

Heat Biologics logoHeat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.

Receive HTBX News and Ratings via Email

Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HTBX
CUSIPN/A
Phone919-240-7133

Debt

Debt-to-Equity RatioN/A
Current Ratio1.11
Quick Ratio1.11

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.51 million
Price / Sales26.74
Cash FlowN/A
Price / CashN/A
Book Value$0.32 per share
Price / Book6.88

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-11,840,000.00
Net Margins-543.30%
Return on Equity-182.19%
Return on Assets-69.51%

Miscellaneous

Employees19
Outstanding Shares18,350,000

Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Heat Biologics shares reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

How were Heat Biologics' earnings last quarter?

Heat Biologics (NASDAQ:HTBX) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.05. The biopharmaceutical company had revenue of $0.75 million for the quarter. Heat Biologics had a negative net margin of 543.30% and a negative return on equity of 182.19%. View Heat Biologics' Earnings History.

When is Heat Biologics' next earnings date?

Heat Biologics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Heat Biologics.

What price target have analysts set for HTBX?

2 equities research analysts have issued twelve-month price targets for Heat Biologics' stock. Their forecasts range from $22.50 to $22.50. On average, they expect Heat Biologics' share price to reach $22.50 in the next year. View Analyst Ratings for Heat Biologics.

Are investors shorting Heat Biologics?

Heat Biologics saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 830,219 shares, an increase of 41.0% from the April 30th total of 588,986 shares. Based on an average daily volume of 6,200,249 shares, the days-to-cover ratio is presently 0.1 days. Approximately 15.3% of the company's shares are sold short.

Who are some of Heat Biologics' key competitors?

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the folowing people:
  • Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 55)
  • Ms. Ann A. Rosar, VP of Fin., Controller & Sec. (Age 66)
  • Dr. Jeff T. Hutchins Ph.D., Chief Scientific Officer (Age 59)
  • Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
  • Colonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor

Has Heat Biologics been receiving favorable news coverage?

News stories about HTBX stock have trended somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Heat Biologics earned a news impact score of 0.07 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.21 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Heat Biologics?

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heat Biologics' stock price today?

One share of HTBX stock can currently be purchased for approximately $2.20.

How big of a company is Heat Biologics?

Heat Biologics has a market capitalization of $36.52 million and generates $1.51 million in revenue each year. Heat Biologics employs 19 workers across the globe.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]


MarketBeat Community Rating for Heat Biologics (HTBX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Heat Biologics (NASDAQ:HTBX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Heat Biologics in the last 12 months. Their average twelve-month price target is $22.50, suggesting that the stock has a possible upside of 922.73%. The high price target for HTBX is $22.50 and the low price target for HTBX is $22.50. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.50$22.50$22.50$21.25
Price Target Upside: 922.73% upside320.56% upside320.56% upside297.20% upside

Heat Biologics (NASDAQ:HTBX) Consensus Price Target History

Price Target History for Heat Biologics (NASDAQ:HTBX)

Heat Biologics (NASDAQ:HTBX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017Griffin SecuritiesInitiated CoverageBuy$22.50HighView Rating Details
7/4/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/8/2016Roth CapitalSet Price TargetBuy$20.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Heat Biologics (NASDAQ:HTBX) Earnings History and Estimates Chart

Earnings by Quarter for Heat Biologics (NASDAQ:HTBX)

Heat Biologics (NASDAQ:HTBX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.07)($0.07)($0.07)
Q2 20181($0.07)($0.07)($0.07)
Q3 20181($0.05)($0.05)($0.05)
Q4 20181($0.05)($0.05)($0.05)

Heat Biologics (NASDAQ HTBX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018N/AView Earnings Details
5/15/2018Q1 2018($0.70)($0.75)$0.75 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.90)($0.60)$0.50 million$0.47 millionViewN/AView Earnings Details
8/14/2017Q2 2017($1.00)($0.90)$0.41 millionViewN/AView Earnings Details
5/11/2017Q1 2017($1.50)($1.20)$0.13 million$0.02 millionViewN/AView Earnings Details
3/31/2017Q4 2016($0.70)($1.20)$0.13 million$0.12 millionViewN/AView Earnings Details
11/10/2016Q3 2016($1.50)($0.80)$0.22 millionViewN/AView Earnings Details
8/15/2016Q2($2.70)($1.70)ViewN/AView Earnings Details
5/11/2016Q1($5.60)($5.00)ViewN/AView Earnings Details
2/18/2016Q4($6.40)($7.80)ViewN/AView Earnings Details
10/30/2015Q3($6.10)($6.20)ViewN/AView Earnings Details
8/13/2015Q2($4.70)($5.60)ViewN/AView Earnings Details
5/14/2015Q1($4.90)($5.70)ViewN/AView Earnings Details
4/16/2015($4.90)($5.60)ViewN/AView Earnings Details
3/27/2015Q4 2014($4.40)($5.60)ViewN/AView Earnings Details
11/14/2014Q314($3.50)($4.60)ViewN/AView Earnings Details
8/14/2014Q214($3.80)($4.40)ViewN/AView Earnings Details
5/13/2014Q1 2014($3.80)($3.60)ViewN/AView Earnings Details
4/1/2014($3.00)($5.50)ViewN/AView Earnings Details
11/14/2013Q3 2013($1.40)($4.80)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Heat Biologics (NASDAQ:HTBX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Heat Biologics (NASDAQ HTBX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 3.27%
Insider Trading History for Heat Biologics (NASDAQ:HTBX)
Institutional Ownership by Quarter for Heat Biologics (NASDAQ:HTBX)

Heat Biologics (NASDAQ HTBX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/23/2016Michael KharitonovDirectorBuy900,000$0.75$675,000.00949,960View SEC Filing  
5/19/2014Jeffrey Alan WolfCEOBuy2,500$4.13$10,325.00View SEC Filing  
5/16/2014Paul BelskyDirectorBuy2,500$4.11$10,275.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Heat Biologics (NASDAQ HTBX) News Headlines

Source:
DateHeadline
Heat Biologics (HTBX) Issues  Earnings ResultsHeat Biologics (HTBX) Issues Earnings Results
www.americanbankingnews.com - May 16 at 10:35 AM
Today’s Research Reports on Stocks to Watch: Heat Biologics, Inc. and Inovio PharmaceuticalsToday’s Research Reports on Stocks to Watch: Heat Biologics, Inc. and Inovio Pharmaceuticals
finance.yahoo.com - May 16 at 9:31 AM
BRIEF-Heat Biologics Inc - QTRLY Loss Per Share $0.75BRIEF-Heat Biologics Inc - QTRLY Loss Per Share $0.75
www.reuters.com - May 15 at 4:59 PM
Form 8-K HEAT BIOLOGICS, INC. For: May 15Form 8-K HEAT BIOLOGICS, INC. For: May 15
www.streetinsider.com - May 15 at 4:59 PM
Heat Biologics Reports First Quarter 2018 Results and Provides Corporate UpdateHeat Biologics Reports First Quarter 2018 Results and Provides Corporate Update
finance.yahoo.com - May 15 at 9:48 AM
Keeping It Simple On The Short SideKeeping It Simple On The Short Side
seekingalpha.com - May 12 at 9:56 AM
Heat Biologics Inc (NASDAQ:HTBX): Risks You Need To Consider Before BuyingHeat Biologics Inc (NASDAQ:HTBX): Risks You Need To Consider Before Buying
finance.yahoo.com - May 9 at 9:20 AM
Heat Biologics, Inc. Announces Closing of $20.7 Million Public OfferingHeat Biologics, Inc. Announces Closing of $20.7 Million Public Offering
finance.yahoo.com - May 8 at 9:13 AM
This Durham company is $20M richerThis Durham company is $20M richer
finance.yahoo.com - May 8 at 9:13 AM
SES: Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with ThemSES: Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them
www.streetinsider.com - May 4 at 9:13 AM
Heat Biologics (HTBX) Prices $18 Million Public OfferingHeat Biologics (HTBX) Prices $18 Million Public Offering
www.streetinsider.com - May 4 at 9:13 AM
Heat Biologics (HTBX) Raised to Hold at ValuEngineHeat Biologics (HTBX) Raised to Hold at ValuEngine
www.americanbankingnews.com - May 4 at 12:41 AM
Heat Biologics, Inc. Prices $18,000,000 Public OfferingHeat Biologics, Inc. Prices $18,000,000 Public Offering
finance.yahoo.com - May 3 at 9:10 AM
Heat Biologics (HTBX) Scheduled to Post Quarterly Earnings on WednesdayHeat Biologics (HTBX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:14 AM
Heat Biologics up 47% premarket ahead of planned equity offeringHeat Biologics up 47% premarket ahead of planned equity offering
seekingalpha.com - May 1 at 9:18 AM
 Heat Biologics (HTBX) Given Consensus Recommendation of "Strong Buy" by Brokerages Heat Biologics (HTBX) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 30 at 5:20 PM
Heat Bio looks to milestones, $15.5M from offeringHeat Bio looks to milestones, $15.5M from offering
finance.yahoo.com - April 23 at 4:33 PM
Heat Biologics (HTBX) Given "Buy" Rating at Noble FinancialHeat Biologics (HTBX) Given "Buy" Rating at Noble Financial
www.americanbankingnews.com - April 19 at 10:12 PM
ValuEngine Downgrades Heat Biologics (HTBX) to Strong SellValuEngine Downgrades Heat Biologics (HTBX) to Strong Sell
www.americanbankingnews.com - April 18 at 4:44 PM
Heat Biologics, Inc.: Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110Heat Biologics, Inc.: Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110
www.finanznachrichten.de - April 18 at 9:20 AM
Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110
finance.yahoo.com - April 18 at 9:20 AM
Who Are Heat Biologics Inc’s (NASDAQ:HTBX) Major Shareholders?Who Are Heat Biologics Inc’s (NASDAQ:HTBX) Major Shareholders?
finance.yahoo.com - April 10 at 4:37 PM
Heat Biologics (HTBX) Upgraded to "Sell" at ValuEngineHeat Biologics (HTBX) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 26 at 5:58 PM
Heat Biologics (HTBX) Reports Positive Data from Phase 2 Trial Evaluating HS-410 (Vesigenurtacel-L) in Combination with Standard of Care BCGHeat Biologics (HTBX) Reports Positive Data from Phase 2 Trial Evaluating HS-410 (Vesigenurtacel-L) in Combination with Standard of Care BCG
www.streetinsider.com - March 26 at 9:42 AM
Heat Biologics, Inc.: Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation PlatformHeat Biologics, Inc.: Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform
www.finanznachrichten.de - March 26 at 9:42 AM
Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation PlatformHeat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform
finance.yahoo.com - March 26 at 9:42 AM
Heat Biologics (HTBX) Stock Rating Lowered by ValuEngineHeat Biologics (HTBX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 25 at 5:22 PM
Heat Biologics (HTBX) vs. Mateon Therapeutics (MATN) Financial AnalysisHeat Biologics (HTBX) vs. Mateon Therapeutics (MATN) Financial Analysis
www.americanbankingnews.com - March 24 at 5:08 AM
On heels of adopting 'poison pill', Heat Bio recruits new scientific expertiseOn heels of adopting 'poison pill', Heat Bio recruits new scientific expertise
finance.yahoo.com - March 20 at 4:28 PM
Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory BoardsHeat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards
finance.yahoo.com - March 19 at 9:29 AM
Heat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering SymposiumHeat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
finance.yahoo.com - March 14 at 5:53 PM
Contrasting bluebird bio (BLUE) & Heat Biologics (HTBX)Contrasting bluebird bio (BLUE) & Heat Biologics (HTBX)
www.americanbankingnews.com - March 14 at 3:07 PM
Heat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in AmsterdamHeat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in Amsterdam
finance.yahoo.com - March 13 at 9:36 AM
Heat Biologics Adopts Stockholder Rights PlanHeat Biologics Adopts Stockholder Rights Plan
finance.yahoo.com - March 12 at 11:16 AM
Has Heat Biologics Inc (NASDAQ:HTBX) Improved Earnings Growth In Recent Times?Has Heat Biologics Inc (NASDAQ:HTBX) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 9 at 9:48 AM
Heat Biologics Reports Fiscal Year 2017 Financial ResultsHeat Biologics Reports Fiscal Year 2017 Financial Results
finance.yahoo.com - March 2 at 5:13 PM
Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - February 28 at 9:12 AM
UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer StudyUPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study
finance.yahoo.com - February 26 at 9:12 AM
Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung CancerHeat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer
finance.yahoo.com - February 20 at 5:01 PM
Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and BeyondHeat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond
finance.yahoo.com - February 15 at 4:41 PM
Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New YorkHeat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York
finance.yahoo.com - February 7 at 9:19 AM
Critical Review: Clearside Biomedical (CLSD) & Heat Biologics (HTBX)Critical Review: Clearside Biomedical (CLSD) & Heat Biologics (HTBX)
www.americanbankingnews.com - February 5 at 11:16 AM
Today’s Research Reports on Trending Tickers: Heat Biologics and ImmunoGenToday’s Research Reports on Trending Tickers: Heat Biologics and ImmunoGen
finance.yahoo.com - February 1 at 9:21 AM
Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer StudyHeat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study
finance.yahoo.com - January 30 at 9:42 AM
Heat latest Triangle biopharma to execute reverse stock splitHeat latest Triangle biopharma to execute reverse stock split
finance.yahoo.com - January 22 at 5:57 PM
Zacks: Heat Biologics, Inc. (HTBX) Given $2.63 Average Price Target by BrokeragesZacks: Heat Biologics, Inc. (HTBX) Given $2.63 Average Price Target by Brokerages
www.americanbankingnews.com - January 20 at 3:38 AM
Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Investors?Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Investors?
finance.yahoo.com - January 2 at 8:59 PM
Heat Biologics, Inc. (HTBX) Short Interest Down 41.6% in NovemberHeat Biologics, Inc. (HTBX) Short Interest Down 41.6% in November
www.americanbankingnews.com - December 16 at 3:42 AM
ETFs with exposure to Heat Biologics, Inc. : December 11, 2017ETFs with exposure to Heat Biologics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:38 PM
Heat Biologics (HTBX) Granted FDA Guidance at Type C Meeting for HS-110 Clinical Trial - StreetInsider.comHeat Biologics (HTBX) Granted FDA Guidance at Type C Meeting for HS-110 Clinical Trial - StreetInsider.com
www.streetinsider.com - December 8 at 11:37 AM

SEC Filings

Heat Biologics (NASDAQ:HTBX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Heat Biologics (NASDAQ:HTBX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Heat Biologics (NASDAQ HTBX) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.